Cantor Fitzgerald set a $18.00 price target on Karyopharm Therapeutics (NASDAQ:KPTI) in a report published on Tuesday. The brokerage currently has a buy rating on the stock.

KPTI has been the subject of several other research reports. started coverage on shares of Karyopharm Therapeutics in a research report on Wednesday, November 15th. They issued a buy rating and a $23.00 price target for the company. Royal Bank of Canada reissued a buy rating and issued a $14.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, October 18th. Zacks Investment Research cut shares of Karyopharm Therapeutics from a buy rating to a hold rating in a research report on Tuesday, November 7th. BidaskClub cut shares of Karyopharm Therapeutics from a hold rating to a sell rating in a research report on Thursday, December 7th. Finally, ValuEngine cut shares of Karyopharm Therapeutics from a sell rating to a strong sell rating in a research report on Wednesday, December 6th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Karyopharm Therapeutics has an average rating of Buy and an average price target of $17.33.

Shares of Karyopharm Therapeutics (NASDAQ KPTI) traded down $0.01 during mid-day trading on Tuesday, reaching $9.24. 407,881 shares of the company’s stock traded hands, compared to its average volume of 127,540. Karyopharm Therapeutics has a 52 week low of $7.48 and a 52 week high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. equities research analysts forecast that Karyopharm Therapeutics will post -2.58 earnings per share for the current fiscal year.

In related news, insider Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $10.39, for a total transaction of $103,900.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Christopher Brett Primiano sold 27,042 shares of Karyopharm Therapeutics stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $10.28, for a total transaction of $277,991.76. Following the sale, the senior vice president now owns 11,381 shares in the company, valued at $116,996.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 45,500 shares of company stock valued at $479,669. Corporate insiders own 14.71% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Swiss National Bank raised its stake in Karyopharm Therapeutics by 39.2% during the 2nd quarter. Swiss National Bank now owns 56,850 shares of the company’s stock worth $514,000 after acquiring an additional 16,000 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in Karyopharm Therapeutics by 4.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock worth $1,111,000 after acquiring an additional 3,762 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in Karyopharm Therapeutics by 16.4% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 510,000 shares of the company’s stock worth $5,600,000 after acquiring an additional 72,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Karyopharm Therapeutics by 31.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after acquiring an additional 384,658 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Karyopharm Therapeutics by 17.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 323,671 shares of the company’s stock worth $2,930,000 after acquiring an additional 47,699 shares in the last quarter. Hedge funds and other institutional investors own 60.92% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/karyopharm-therapeutics-kpti-given-a-18-00-price-target-by-cantor-fitzgerald-analysts/1768046.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.